Dr. William E. Luginbuhl
Claim this profileChester County Hospital
Studies Ovarian Cancer
Studies Breast Cancer
14 reported clinical trials
50 drugs studied
Area of expertise
1Ovarian Cancer
Stage II
Stage III
Stage IV
2Breast Cancer
HER2 positive
ER negative
HER2 negative
Affiliated Hospitals
Clinical Trials William E. Luginbuhl is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
More about William E. Luginbuhl
Clinical Trial Related6 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments William E. Luginbuhl has experience with
- Bevacizumab
- Carboplatin
- Paclitaxel
- Letrozole
- Paclitaxel, Carboplatin
- Irinotecan
Breakdown of trials William E. Luginbuhl has run
Ovarian Cancer
Breast Cancer
Breast cancer
Ovarian Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does William E. Luginbuhl specialize in?
William E. Luginbuhl focuses on Ovarian Cancer and Breast Cancer. In particular, much of their work with Ovarian Cancer has involved Stage II patients, or patients who are Stage III.
Is William E. Luginbuhl currently recruiting for clinical trials?
Yes, William E. Luginbuhl is currently recruiting for 4 clinical trials in West Chester Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that William E. Luginbuhl has studied deeply?
Yes, William E. Luginbuhl has studied treatments such as Bevacizumab, Carboplatin, Paclitaxel.
What is the best way to schedule an appointment with William E. Luginbuhl?
Apply for one of the trials that William E. Luginbuhl is conducting.
What is the office address of William E. Luginbuhl?
The office of William E. Luginbuhl is located at: Chester County Hospital, West Chester, Pennsylvania 19380 United States. This is the address for their practice at the Chester County Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.